Evidence map›Paper›PMID 34351732›Full record

ArticleACS chemical biology2021

Synthesis of 3-

Jine Li, Guowei Su, Yongmei Xu, Katelyn Arnold, Vijayakanth Pagadala, Chunyu Wang, Jian Liu

Abstract read
In one paragraph

Article in ACS chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Synthetic biology for heparin biomanufacturing.Bioresources and bioprocessing · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Emerging chemical and biochemical tools for studying 3-American journal of physiology. Cell physiology · 2022
    Review
  8. 3-Computational and structural biotechnology journal · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jine LiDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Guowei SuGlycan Therapeutics Corporation, 617 Hutton Street, Raleigh, North Carolina 27606, United States.
Yongmei XuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Katelyn ArnoldDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
Vijayakanth PagadalaGlycan Therapeutics Corporation, 617 Hutton Street, Raleigh, North Carolina 27606, United States.
Chunyu WangDepartment of Biological Sciences, Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, New York 12180, United States.ORCID 0000-0001-5165-7959
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8552-1400

Funding

In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
Development of dekaparin to replace animal-sourced heparinR44HL139187 · NHLBI · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2025
$4.2M
Synthetic Heparan Sulfate: Probing Biosynthesis to Prepare Defined DrugsR01HL062244 · NHLBI · UNIVERSITY OF IOWA · PI DEANGELIS, PAUL L, LINHARDT, ROBERT J · 2001 to 2016
$4.1M
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating GlycosaminoglycansR44GM134738 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2021
$3.2M
Heparan Sulfate 3-O-Sulfation in Transcellular Propagation of Tauopathy in Alzheimer's DiseaseRF1AG069039 · NIA · RENSSELAER POLYTECHNIC INSTITUTE · PI LINHARDT, ROBERT J, LIU, JIAN · 2020 to 2020
$2.6M
Developing Heparan Sulfate Glycan ArrayR44GM123792 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI SU, GUOWEI · 2020 to 2021
$2.4M
Reactor for Insect Cell CultureR42GM128484 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI XU, YONGMEI · 2018 to 2020
$1.9M
Synthesis and Pharmacological Evaluation of Homogenous Ultra-Low Molecular Weight HeparinsR01HL144970 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN · 2019 to 2021
$946k
Developing Heparan Sulfate Glycan ArrayR41GM123792 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI LIU, JIAN · 2017 to 2018
$297k
Development of a New Carbohydrate-based Anticoagulant DrugR41HL139187 · NHLBI · GLYCAN THERAPEUTICS CORPORATION · PI LIU, JIAN · 2017 to 2017
$225k
NHLBI NIH HHS R01 HL062244NHLBI NIH HHS R01 HL094463NHLBI NIH HHS R01 HL144970NHLBI NIH HHS R41 HL139187NHLBI NIH HHS R44 HL139187NIA NIH HHS RF1 AG069039NIGMS NIH HHS R41 GM123792NIGMS NIH HHS R42 GM128484NIGMS NIH HHS R44 GM123792NIGMS NIH HHS R44 GM134738
6 · The paper itself

Abstract

Heparan sulfate (HS) 3-

Indexed as

AnimalsCarbohydrate SequenceFactor XaFactor Xa InhibitorsHMGB1 ProteinIsoenzymesMiceOligosaccharidesRecombinant ProteinsSf9 CellsSulfotransferasestau ProteinsFactor XaFactor Xa Inhibitorsheparitin sulfotransferaseHMGB1 ProteinHMGB1 protein, mouseIsoenzymesOligosaccharidesRecombinant ProteinsSulfotransferasestau Proteins

Identifiers

PMID34351732
PMCPMC8526403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.